Deciphering gliomagenesis from genome-wide association studies
Neuro-Oncology · 2023
DOI: 10.1093/neuonc/noad057 ↗Kurz gefasst
Editorial in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Luc Bauchet und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, CHU Montpellier, Montpellier, France. Hauptthemen laut MEDLINE: Genome-Wide Association Study, Glioma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The etiology of gliomas is poorly understood. Differences in the incidence of glioma between regions have suggested environmental risk factors: Many have been suspected—including pesticides, nonionizing radiations, diet, pollution, socioeconomic status, etc.—but the only validated associations are ionizing radiation (which increases risk in both adults and children) and history of allergies (which decreases risk in adults). Regarding genetics, around 3%–5% of glioma patients have a first-degree relative affected also by glioma. It is estimated that 1%–2% of adult and 4% of pediatric cases are due to known Mendelian disorders, mostly due to loss-of-function mutations in tumor suppressor genes, such as tumor protein p53 (TP53), mismatch repair (MMR) genes, and neurofibromin 1 (NF1) mutations.1 Besides these known predisposition syndromes, agnostic unbiased approaches performed over the last 15 years by genome-wide association studies (GWAS) have identified now more than 26 unequivocal genetic loci associated with the risk of gliomas, the last study is based on 12 496 cases and 18 190 controls.2 Overall heritability is estimated to represent 25% of the occurrence of gliomas, as estimated by genome-wide complex trait analysis.3 These loci are mapped by single nucleotide polymorphism (SNP) which are anonymous variants, mostly located in noncoding regions, and not associated with biological function, but rather supposed to be genetically linked to a variant involved in gliomagenesis. It is particularly striking to note that GWAS, which is an agnostic approach devoid of any biological presupposition, leads to unequivocal loci mapping in the close vicinity of genes involved in gliomagenesis such as epidermal growth factor receptor (EGFR), cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B), telomerase reverse transcriptase (Tert), TP53, and isocitrate dehydrogenase 1 (IDH1).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, CHU Montpellier, Montpellier, France.
- IGF, University of Montpellier, CNRS, INSERM, Montpellier, France.
- French Brain Tumor DataBase, Registre des Tumeurs de l'Hérault, ICM, Montpellier, France.
- AP-HP, Hôpital de la Pitié-Salpêtrière, Service de Neurologie 2, Paris, France.
- Sorbonne Université, INSERM Unité 1127, CNRS UMR 7225, Paris Brain Institute, Paris, France.
ORCID-Profile: Luc Bauchet
Zitieren
APA
Bauchet, L., & Sanson, M. (2023). Deciphering gliomagenesis from genome-wide association studies. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad057
Vancouver
Bauchet L, Sanson M. Deciphering gliomagenesis from genome-wide association studies. Neuro-Oncology. 2023. doi:10.1093/neuonc/noad057
BibTeX
@article{Bauchet2023,
author = {Bauchet, Luc and Sanson, Marc},
title = {Deciphering gliomagenesis from genome-wide association studies},
journal = {Neuro-Oncology},
year = {2023},
doi = {10.1093/neuonc/noad057}
}
EUVIMED